Early treatment with dexamethasone intravitreal implants in diabetic macular edema: Naïve versus refractory patients

Purpose: To assess the efficacy and safety of dexamethasone 0.7 mg implants (DEX-I) in patients with diabetic macular edema (DME) either naïve to therapy or refractory to anti-VEGF treatment, in a single-center, real-world setting. Methods: Patients diagnosed with DME and treated with DEX-I were retrospectively enrolled in the study and split in two groups: naïve (Group 1, n = 64) and refractory (Group 2, n = 64) to treatment. Patients were evaluated at baseline, at 1 month, and every 3 months after each DEX-I implant. Main outcome measures were change in best-corrected visual acuity (BCVA) and central macular thickness (CMT) from baseline to follow-up visits. Results: Significant improvements in BCVA were observed in treatment-naïve patients at 6 months following the first and second DEX-I injection (p = 0.0023 and p = 0.0063, respectively), with significant reductions in mean CMT at 6 months after all DEX implants. In treatment-refractory patients, mean CMT was significantly reduced from baseline to 6 months (p < 0.05) after all DEX-I injections, although no changes were observed in BCVA. Conclusions: DEX-I improved visual acuity and macular edema mostly in treatment-naïve patients, suggesting DEX-I may be a viable first-line treatment option in DME.

[1]  Lihteh Wu,et al.  Corticosteroids for Diabetic Macular Edema , 2019, Taiwan journal of ophthalmology.

[2]  A. Koh,et al.  First-line treatment algorithm and guidelines in center-involving diabetic macular edema , 2019, European journal of ophthalmology.

[3]  V. Castro-Navarro,et al.  Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema , 2019, BMC Ophthalmology.

[4]  M. Maia,et al.  Effectiveness and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: A Real-World Experience , 2018, Ophthalmologica.

[5]  N. Bressler,et al.  Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial , 2018, JAMA ophthalmology.

[6]  S. Vujosevic,et al.  Imaging retinal inflammatory biomarkers after intravitreal steroid and anti‐VEGF treatment in diabetic macular oedema , 2017, Acta ophthalmologica.

[7]  Bianca S. Gerendas,et al.  Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA) , 2017, Ophthalmologica.

[8]  N. Voirin,et al.  REAL-LIFE STUDY IN DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT: The Reldex Study , 2017, Retina.

[9]  M. Varano,et al.  INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY , 2016, Retina.

[10]  N. Bressler,et al.  Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment. , 2016, JAMA ophthalmology.

[11]  M. Romano,et al.  Intravitreal Injection of Ozurdex® Implant in Patients with Persistent Diabetic Macular Edema, with Six-Month Follow-Up , 2016, Ophthalmology and eye diseases.

[12]  A. Loewenstein,et al.  Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study , 2015, BMC Ophthalmology.

[13]  J. J. Escobar-Barranco,et al.  Dexamethasone Implants in Patients with Naïve or Refractory Diffuse Diabetic Macular Edema , 2015, Ophthalmologica.

[14]  M. Gillies,et al.  A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. , 2014, Ophthalmology.

[15]  S. Whitcup,et al.  Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. , 2014, Ophthalmology.

[16]  T. Yamashita,et al.  RETINAL MORPHOLOGIC CHANGES AND CONCENTRATIONS OF CYTOKINES IN EYES WITH DIABETIC MACULAR EDEMA , 2014, Retina.

[17]  M. Lukić,et al.  TREATMENT OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR–RESISTANT DIABETIC MACULAR EDEMA WITH DEXAMETHASONE INTRAVITREAL IMPLANT , 2014, Retina.

[18]  I. Kim,et al.  Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. , 2011, American journal of ophthalmology.

[19]  J. Chhablani,et al.  DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study , 2019, Retina.

[20]  T. Mimura,et al.  Association of vitreous inflammatory factors with diabetic macular edema. , 2009, Ophthalmology.